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Objectives The goal of this study was to establish a patient-specific human-induced pluripotent stem cells (hiPSCs) model
of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Background CPVT is a familial arrhythmogenic syndrome characterized by abnormal calcium (Ca2) handling, ventricular ar-
rhythmias, and sudden cardiac death.
Methods Dermal fibroblasts were obtained from a CPVT patient due to the M4109R heterozygous point RYR2 mutation
and reprogrammed to generate the CPVT-hiPSCs. The patient-specific hiPSCs were coaxed to differentiate into
the cardiac lineage and compared with healthy control hiPSCs-derived cardiomyocytes (hiPSCs-CMs).
Results Intracellular electrophysiological recordings demonstrated the development of delayed afterdepolarizations in
69% of the CPVT-hiPSCs-CMs compared with 11% in healthy control cardiomyocytes. Adrenergic stimulation by
isoproterenol (1 M) or forskolin (5 M) increased the frequency and magnitude of afterdepolarizations and also
led to development of triggered activity in the CPVT-hiPSCs-CMs. In contrast, flecainide (10 M) and thapsigargin
(10 M) eliminated all afterdepolarizations in these cells. The latter finding suggests an important role for inter-
nal Ca2 stores in the pathogenesis of delayed afterdepolarizations. Laser-confocal Ca2 imaging revealed sig-
nificant whole-cell [Ca2] transient irregularities (frequent local and large-storage Ca2-release events, broad
and double-humped transients, and triggered activity) in the CPVT cardiomyocytes that worsened with adrenergic
stimulation and Ca2 overload and improved with beta-blockers. Store-overload–induced Ca2 release was also
identified in the hiPSCs-CMs and the threshold for such events was significantly reduced in the CPVT cells.
Conclusions This study highlights the potential of hiPSCs for studying inherited arrhythmogenic syndromes, in general, and
CPVT specifically. As such, it represents a promising paradigm to study disease mechanisms, optimize patient
care, and aid in the development of new therapies. (J Am Coll Cardiol 2012;60:990–1000) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.066g
t
cCatecholaminergic polymorphic ventricular tachycardia
(CPVT) is a familial arrhythmogenic disorder caused by
unstable sarcoplasmic reticulum (SR) calcium (Ca2) stor-
age leading to exercise- or emotion-induced ventricular
tachyarrhythmias and sudden cardiac death (1,2). The
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Manuscript received October 20, 2011; revised manuscript received January 25,
2012, accepted February 15, 2012.majority of CPVT cases are associated with dominant
mutations in the cardiac ryanodine receptor gene (RyR2)
with variable penetrance (CPVT1) (3,4), whereas the mi-
nority of cases result from recessive mutations in the cardiac
calsequestrin isoform 2 (CASQ2) gene (5). Investigation of
the mutations giving rise to CPVT provided important
See page 1001
insights into the mechanisms underlying this disease and to
the processes governing cardiomyocyte Ca2 handling in
eneral (6). Nevertheless, among the hurdles in studying
his disease process has been the lack of appropriate human
ardiac tissue models and the inability to study patient-
pecific disease variations.
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September 11, 2012:990–1000 CPVT Modeling With Human-Induced Pluripotent Stem CellsThe development of the groundbreaking human- induced
pluripotent stem cells (hiPSCs) technology (7,8) may pro-
vide a possible solution to the aforementioned challenges.
The iPSCs approach, pioneered by Takahashi and Ya-
manaka, allows the reprogramming of adult somatic cells
into pluripotent stem cells by ectopic expression of a set of
transcription factors (9). Subsequent studies showed the
robust ability to generate hiPSCs and to coax their differ-
entiation into cardiomyocytes (10,11). More recent proof-
of-concept studies demonstrated the ability to establish
patient- and disease-specific hiPSCs-derived cardiomyocytes
(hiPSCs-CMs) that could recapitulate the abnormal cardiac
henotypes of Leopard and long-QT syndromes (12–14).
n the current report, our goal was to establish an hiPSCs
odel of CPVT. We hypothesized that the generated
PVT-hiPSCs-CMs will recapitulate the disease pheno-
ype in vitro, providing insights into disease mechanisms
nd offering a unique platform to evaluate patient-specific
herapies.
ethods
iPSCs generation and cardiomyocyte differentiation.
he patient-specific hiPSCs clones were generated by
etroviral reprogramming of dermal fibroblasts with Oct4,
Sox-2, and Klf-4 followed by valproic acid treatment as
reviously described (13,15). Cardiomyocyte differentiation
as induced using the embryoid body (EB) differentiating
ystem. Briefly, undifferentiated hiPSCs were removed from
he mouse embryonic fibroblast feeder-layer, dispersed into
ell-clumps using collagenase type IV (300 U/ml [Life
echnologies Corporation, Grand Island, New York]),
ultivated in suspension for 10 days as EBs, and plated on
elatin-coated culture dishes (11).
mmunostainings. Specimens were fixed with 4% parafor-
aldehyde, permeabilized with 1% Triton, blocked with 5%
orse serum, and incubated with primary antibodies target-
ng: Oct4, Tra1-60 (Santa-Cruz Biotechnology, Santa
ruz, California), Nanog (Peprotech, Rehovot, Israel),
SEA-4 (R&D Systems, Minneapolis, Minnesota), tro-
onin I, ryanodine receptor (Chemicon, Merck Millipore,
illerica, Massachusetts), and sarcomeric alpha actinin
Sigma-Aldrich, St. Louis, Missouri). The preparations
ere incubated with secondary antibodies and examined
sing a laser-scanning confocal microscope (Zeiss LSM-
10-PASCAL). Alkaline phosphatase staining of hiPSCs
olonies was performed using a Sigma detection kit.
eratoma formation. Undifferentiated hiPSCs were dis-
ociated with collagenase-IV and injected subcutaneously
nto SCID/beige mice. Tumor samples were collected at 6
o 8 weeks, fixed in 4%-formaldehyde, embedded in paraf-
n, sectioned, and stained with hematoxylin and eosin.
enomic sequencing. Genomic DNA was isolated by
sing the high-pure polymerase chain reaction (PCR) tem-
late preparation kit (Roche, Basel, Switzerland). The
elevant DNA fragment of the RYR2 gene was amplified byCR using 100-ng genomic
NA. Primers are detailed in
nline Table 1. PCR products
ere then sequenced.
ene expression analysis. RNA
was isolated by using the RNeasy
Plus Mini Kit (Qiagen Inc., Valen-
cia, California). Reverse transcrip-
tion into cDNA was conducted
with the high-capacity cDNA
reverse-transcription kit (Applied
Biosystems). Real-time polymerase
chain reaction (RT-PCR) studies
were performed by using the
DreamTaq Master Mix (Ferments
Molecular Biology Tools, Thermo
Fisher Scientific, Waltham, Massa-
chusetts). Primers are listed in
Online Table 1. Each RT-PCR in-
cluded 2 min at 93°C followed by 27
to 35 cycles of 30 s at 93°C, 60 s at
0°C, and 40 s at 72°C.
RT-PCR studies were con-
ucted in triplicate by using the
ast SYBR Green Master Mix
Applied Biosystems, Life Tech-
ologies Corporation). Primers
re detailed in Online Table 2.
amples were cycled by using the Fast ABI-7500 sequence
etector. Conditions were as follows: 20 s at 95°C followed
by 40 cycles of 3 s at 95°C and 30 s at 60°C. Cycle threshold
was calculated by using default settings for the real-time
sequence detection software (Applied Biosystems).
Whole-cell patch-clamp recordings. Contracting EBs
were enzymatically dispersed (1 mg/ml collagenase B
[Roche]) and attached to fibronectin-coated glass coverslips.
Action potentials (APs) were recorded from spontaneously
contracting and quiescent hiPSCs-CMs at 32°C under
spontaneous and paced (1 Hz) rhythms. The tyrode solution
included (in mmol/l: NaCl 140; KCl 4; CaCl2 2; MgCl2 1;
HEPES 10; and glucose 5 (pH 7.4; NaOH). The pipette
solution contained (in mmol/l): K-aspartate 120; KCl 20;
MgCl2 1; Na2ATP 4; GTP 0.1; HEPES 10; and glucose 10
(pH 7.2; KOH). APs were recorded in the current-clamp
mode with Axopatch 200B, Digidata 1322A, and pClamp 9
(Axon Instruments, Sunnyvale, California).
Microelectrodearray recordings. Microelectrodearray re-
cordings (Multichannels Systems, Reutlingen, Germany)
were performed as previously described (11,16). Local
activation times were determined at each electrode and used
for generation of color-coded activation maps.
Ca2 imaging. Cells were loaded with 5M fluo-4 fluo-
rescent Ca2 indicator (Molecular Probes, Life Technolo-
ies Corporation) to allow recordings of whole-cell [Ca2]i
Abbreviations
and Acronyms
AP  action potential
CASQ2  cardiac
calsequestrin isoform 2
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
DADs  delayed
afterdepolarizations
EB  embryoid body
hiPSC  human-induced
pluripotent stem cell
hiPSCs-CMs  human-
induced pluripotent stem
cells–derived
cardiomyocytes
PCR  polymerase chain
reaction
RT-PCR  real-time
polymerase chain reaction
RyR2  ryanodine receptor
isoform 2
SOICR  store-overload–
induced Ca2 release
SR  sarcoplasmic
reticulumtransients as previously reported (15). Experiments were
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CPVT Modeling With Human-Induced Pluripotent Stem Cells September 11, 2012:990–1000conducted during continuous tyrode perfusion that included
(in mmol/l) NaCl 140; KCl 5.4; CaCl2 1.8; MgCl2 1;
EPES 10; and glucose 10. [Ca2]i imaging was per-
formed by using the Zeiss LSM-700 confocal system. To
evaluate for store-overload–induced Ca2 release (SOICR),
e used a modification of the method described by Jiang et
l. (17,18). In brief, repeated Ca2 imaging from the
hiPSCs-CMCs was performed at increasing extracellular
[Ca2]o concentrations (0.1 to 4 mmol/l) in the presence of
etrodotoxin (10 M). Tetrodotoxin was added to eliminate
P-dependent Ca2 releases, thereby unmasking only
OICR events.
tatistical analysis. Continuous variables are reported as
ean  SEM. Categorical variables are expressed as fre-
uencies. Categorical differences between groups were eval-
ated by using the chi-square test. Differences between
roup means were compared by using the unpaired Student
test. These statistical tests were applied to comparisons
etween the cells obtained from the 2 individuals studied
Figure 1 Derivation and Characterization of the CPVT-hiPSCs
(A) Electrocardiogram of the catecholaminergic polymorphic ventricular tachycardia
tachycardia during epinephrine testing. (B) Immunostaining of undifferentiated CP
potent markers OCT4, NANOG, SSEA4, and TRA1-60. Note also the positive staini
gene identifying the M4109R heterozygous point mutation in the CPVT-hiPSCs.nd cannot necessarily be generalized to differences between
atient populations. p  0.05 was considered statistically
ignificant.
esults
erivation of the patient-specific CPVT-hiPSCs.
ermal fibroblasts were obtained from a 30-year-old
oman diagnosed with CPVT1. The patient comes from a
amily with a significant history of sudden cardiac death
including the patient’s father, brother, sister, and nephews)
19) and was implanted prophylactically with an implant-
ble cardioverter-defibrillator. An episode of nonsustained
entricular tachycardia was documented during device
ollow-up and after an epinephrine stress test (Fig. 1A).
enetic workup revealed a heterozygous missense mutation
M4109R) in the RyR2 gene in all affected family members (19).
Several CPVT-hiPSCs clones were generated during
eprogramming of the patient’s fibroblasts, 2 of which were
T) patient showing the development of nonsustained polymorphic ventricular
an-induced pluripotent stem cell (hiPSC) colonies (from 2 clones) for the pluri-
alkaline-phosphatase (AP [right]). Bars: 100 m. (C) Sequencing of the RYR2(CPV
VT–hum
ng for
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September 11, 2012:990–1000 CPVT Modeling With Human-Induced Pluripotent Stem Cellspropagated and used for cardiomyocyte differentiation and
characterization (Fig. 1B). Similar hiPSCs previously cre-
ated from fibroblasts of a healthy individual (15) served as
controls. Importantly, the M4109R mutation was identified
in the CPVT-hiPSCs but not in the healthy control cells
(Fig. 1C).
The CPVT-hiPSCs colonies exhibited characteristic hu-
man embryonic stem cell morphology; stained positively for
the pluripotency markers NANOG, OCT4, SSEA-4, and
TRA1-60 (Fig. 1B); displayed alkaline phosphatase activity
(Fig. 1B [right panel]); and maintained a normal karyotype
(data not shown). Pluripotency of the CPVT-hiPSCs was
confirmed by the presence of cell-derivatives of all 3
germ-layers in differentiating EBs (Fig. 2A). Note the
positive staining for nestin (ectodermal marker), alpha-
fetoprotein (endoderm), and desmin (mesoderm) (Fig. 2A).
Figure 2 Characterization of the CPVT-hiPSCs
(A) Immunostaining of in vitro differentiating embryoid bodies from 2 CPVT-hiPSC
derm). Scale bars: 100 m. (B) Teratoma formation in SCID/beige mice after inje
(ectoderm), columnar-lining epithelium (endoderm), and hyaline cartilage (mesoder
showing the down-regulation of OCT3/4, KLF4, and SOX2 transgenes in the CPVT-
Values are normalized to the housekeeping gene RPL-7 and expressed as mean 
fected with the 3 plasmids to produce reprogramming virions. (D) Real-time quant
SOX2, FOXD3, NANOG, and REX1 in the CPVT-hiPSC clones. Values are normalized
(RQ) are relative to levels in the patient’s fibroblasts. Abbreviations as in Figure 1Similarly, injection of undifferentiated CPVT-hiPSCs into
SCID/beige mice led to the formation of teratomas,
containing advanced tissue derivatives of all 3 germ layers
(Fig. 2B). Finally, all clones showed silencing of the 3
retroviral transgenes (Fig. 2C) and reactivation of endog-
enous pluripotency genes (OCT4, SOX2, NANOG,
FOXD3, and REX1) (Fig. 2D), indicating successful
reprogramming.
Cardiomyocyte differentiation. We next used the EB
differentiation system to coax the differentiation of the
hiPSCs into the cardiac lineage. Both the healthy control
and CPVT hiPSCs lines showed similar cardiomyocyte
differentiation potential as judged by the number of con-
tracting EBs generated during differentiation (Fig. 3A) and
by comparable quantitative expression of cardiac-specific
genes by the differentiating cells (Fig. 3B).
for nestin (ectoderm), alpha-fetoprotein (AFP; endoderm), and desmin (meso-
f undifferentiated CPVT-hiPSCs. Note the presence of pigmented epithelium
ale bars: 100 m. (C) Real-time quantitative polymerase chain reaction (PCR)
clones (C1 and C2). Patient’s fibroblasts (Fib.) were used as negative controls.
. Expression values (RQ) are relative to HEK293T cells (HEK) transiently trans-
PCR evaluating the endogenous levels of the pluripotency genes OCT 3/4,
e housekeeping gene RPL-7 and expressed as mean  SEM. Expression valuesclones
ction o
m). Sc
hiPSC
SEM
itative
to th
.
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CPVT Modeling With Human-Induced Pluripotent Stem Cells September 11, 2012:990–1000Gene expression analysis (Fig. 3C) revealed the expres-
sion of cardiac-specific transcription factors (NKX2.5) and
structural genes (MLC-2V, MYH-6, MYH-7 and cTnI) by
Figure 3 Phenotypic Characterization of CPVT-hiPSCs-CMs
(A) Summary of the average number of beating embryoid bodies (EBs)/plate gene
control hiPSCs (p  0.86). (B) Real-time quantitative PCR of in vitro differentiating
specific markers (cTnI  cardiac-troponin I; MLC-2V  myosin-light-chain 2-ventricu
CPVT-hiPSCs-CMCs. Values are normalized to the RPL-7 gene and displayed as me
genes by the CPVT-hiPSCs-CMs (right). Undifferentiated (Undiff) hiPSCs (left) expre
sarcomeric-alpha-actinin. Bars: 25 m. (E) Immunostainings of CPVT (top) and co
alpha-actinin (red, middle). Right: merged image. Bars: 25 m. (F) Real-time qua
healthy control hiPSCs-CMs. Quantification is relative to control cells. Values are n
recordings from the control and CPVT hiPSC-CMCs showing ventricular-like, atrial-li
CPVT-hiPSC-CMs (left) and the resulting color-coded activation map (right). Abbrevhe CPVT-hiPSCs-CMCs. Similarly, immunostainingstudies targeting the sarcomeric proteins troponin I and
alpha-actinin confirmed the cardiomyocyte phenotype of
these cells (Fig. 3D). These experiments also verified the
uring differentiation. Note the similar differentiation capacities of the CPVT and
and healthy control hiPSCs. Note comparable expression levels of cardiac-
YH6  alpha-myosin-heavy-chain). Quantification is relative to levels in the
SEM. (C) Semi-quantitative real-time PCR showing expression of cardiac-specific
T4 and NANOG. (D) Immunostainings of CPVT-hiPSCs-CMs for TnI and
bottom) hiPSCs-CMs for ryanodine-receptor (RYR) (green, left) and sarcomeric-
e PCR analysis showing equivalent levels of RyR2 expression between CPVT and
ized to RPL-7 gene and presented as mean  SEM. (G) Action potential (AP)
d nodal-like morphologies. (H) Microelectrodearray recordings (left) from the
s as in Figures 1 and 2.rated d
CPVT
lar; M
an 
ss OC
ntrol (
ntitativ
ormal
ke, an
iationpresence of the major SR Ca2 release channels (RyR2)
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September 11, 2012:990–1000 CPVT Modeling With Human-Induced Pluripotent Stem Cellsin the CPVT-hiPSCs-CMs (Fig. 3E). No differences
were noted in RyR2 expression between healthy and
diseased hiPSCs-CMs at the mRNA level (Fig. 3F) and
also in protein expression and subcellular localization as
judged by immunostaining analysis (Fig. 3E).
Intracellular (patch-clamp) and extracellular (multielec-
trode) electrophysiological recordings established the pres-
ence of cardiac-specific APs by the CPVT-hiPSCs-CMs at
the cellular level (Fig. 3G) and the development of a
functional syncytium at the tissue level (Fig. 3H). Similar to
previous reports (10,13), 3 types of AP morphologies were
recorded from the CPVT-hiPSCs-CMs (Fig. 3G). The
most dominant (57% of cells) was the ventricular-like
morphology, with atrial-like (29%), and nodal-like (14%)
types being less prevalent.
Figure 4 AP Recordings
(A) Action potential (AP) recordings from CPVT-hiPSCs-CMs. Note the development
noted during late phase 3, either alone (middle) or together with phase 4 afterdep
cells lacked afterdepolarization (left), small delayed afterdepolarizations (DADs) we
hiPSCs-CMs displaying afterdepolarizations.*p  0.01. (D) AP recordings from con
rates. Arrows indicate afterdepolarizations. Abbreviations as in Figure 1.CPVT-hiPSCs-CMs display afterdepolarizations. De-
tailed analysis of AP properties (amplitude, upstroke-
velocity, durations, and resting membrane potential) re-
vealed no significant differences between the healthy control
and CVPT hiPSCs-CMs (Online Table 3). In contrast,
marked differences were noted in the cardiomyocytes’ ar-
rhythmogenic potential. Hence, clear delayed afterdepolar-
izations (DADs) developed in most CPVT-hiPSCs-CMs
when paced at 0.5 to 1 Hz (Fig. 4A). These DADs were
observed in 69% (22 of 32) of the CPVT-hiPSCs-CMs
studied (Fig. 4C), with a mean amplitude of 13.0 8.2 mV.
In contrast, DADs were only seen in 11% (3 of 28; p 
0.01) of the healthy control hiPSCs-CMs (Figs. 4B and
4C) and their amplitude was significantly smaller (5.7 3.9
mV; p  0.01).
ase 4 afterdepolarizations (left). Occasionally, afterdepolarizations were also
ations (right). (B) AP recordings from control hiPSCs-CMs. Note that while most
ted in some cells (right). (C) Summary of the percentage of CPVT and control
nd CPVT-hiPSC-CMs during spontaneous (slow) and more rapid (1-Hz pacing)of ph
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CPVT Modeling With Human-Induced Pluripotent Stem Cells September 11, 2012:990–1000In the majority of CPVT-hiPSCs-CMs (17 of 22), after-
depolarizations were initiated during phase 4 of the AP (Fig.
A [left]). In the remaining 5 cells, afterdepolarizations were
lso noted during late phase 3 (Fig. 4A [middle/right panels]).
he severity of the afterdepolarizations in the CPVT-hiPSCs-
Ms seemed to correlate with beating frequency (Fig. 4D),
nd they could be identified both during the stimulation train
Fig. 5A [top]) and immediately after termination of pacing
Fig. 5A [bottom]). Finally, similar percentages of cells dis-
laying afterdepolarizations (62% and 73%) were found in 2
ifferent independently derived CPVT-hiPSCs clones, thus
ssuring that the aforementioned findings were not related to
lonal variations.
Figure 5 Pharmacological Interventions
AP recordings from the CPVT-hiPSCs-CMs during stimulation (top) and after terminatio
forskolin increased the magnitude and frequency of DADs (arrows) and also induced
baseline recordings during 1-Hz stimulation (C); isoproterenol led to the development
recordings from CPVT-hiPSC-CMs at baseline (afterdepolarizations identified with arrow
the forskolin-treated hiPSCs-CMCs at baseline (left) and after treatment with thapsigaAdrenergic stimulation. Because arrhythmias in CPVT
are related to exercise or emotional stress, we next evaluated the
impact of activation of the adrenergic signaling pathway.
Application of forskolin (5 M), a direct activator of adenylate
cyclase, significantly increased the frequency and amplitude of
DADs in 83% (5 of 6) of the paced CPVT-hiPSCs-CMs
studied and even led to the formation of triggered activity beats
in 2 cells (Fig. 5B [top]). We next studied quiescent CPVT-
hiPSCs-CMs. Under baseline conditions, with cessation of
pacing (Fig. 5A [bottom]), low-amplitude DADs were gen-
erated at relatively long coupling intervals. Application of
forskolin led to development of multiple DADs in these
CPVT-hiPSCs-CMs (exhibiting higher amplitudes and
cing (bottom) at (A) baseline and (B) after application of forskolin 5 M. Note that
d activity (TA). (C to E) Isoproterenol effects on the CPVT-hiPSCs-CM. Shown are
s (arrows) and TA during stimulation (D) and after termination of pacing (E). (F) AP
) and after flecainide treatment (right). (G) Magnification of the postpacing period in
ght). Note the disappearance of DADs. Abbreviations as in Figure 1.n of pa
triggere
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September 11, 2012:990–1000 CPVT Modeling With Human-Induced Pluripotent Stem Cellsshorter coupling intervals) and even to DAD-mediated trig-
gered activity (Fig. 5B [bottom]).
Application of the beta-agonist isoproterenol also had a
proarrhythmic effect in the CPVT-hiPSCs-CMs. Thus,
compared with baseline recordings (Fig. 5C), isoproterenol
(1 M) administration resulted in the development of
afterdepolarizations in 4 of the 6 cells studied, both during
the stimulation train (1 Hz; Fig. 5D), as well as in quiescent
cells, after termination of pacing (Fig. 5E). In the latter
case, triggered activity was also noted.
Effects of flecainide. A unique advantage of the hiPSCs
technology is the potential to screen the effects of therapeu-
tic interventions in a patient-specific manner. To test the
feasibility of this concept, we evaluated the effects of
flecainide, an antiarrhythmic agent suggested to display
antiarrhythmic properties in CPVT (20). As shown in
Figure 5F, flecainide 10 M completely eliminated or
significantly decreased afterdepolarizations in all of the
patient-specific CPVT-hiPSCs-CMs studied (n  6).
Role of intracellular Ca2 stores. To verify the role of
internal Ca2 stores in the pathogenesis of the observed
DADs, we treated the CPVT-hiPSCs-CMs with thapsi-
gargin (10 M), a specific inhibitor of the sarcoplasmic
eticulum calcium ATPase pump. Blocking of Ca2 re-
uptake into the SR gradually depletes intracellular Ca2
stores. We next evaluated the ability of forskolin-treated
cells to develop DADs before and after thapsigargin treat-
ment. As shown in Figure 5G, thapsigargin significantly
depressed postpacing afterdepolarizations, indicating the
important role of internal Ca2 stores in their formation.
a2 imaging. To further evaluate calcium handling, we
performed laser-confocal Ca2-imaging of fluo4-loaded
hiPSCs-CMs. As depicted in Figures 6A to 6C, the
CPVT-hiPSCs-CMs displayed significant whole-cell
[Ca2]i transient abnormalities when compared with
ealthy control cells (Figs. 6D to 6E). These abnormalities
ere noted in 77% (23 of 30) of the CPVT-hiPSCs-CMs
nd were manifested by 1 of the following: 1) frequent
ocal Ca2 release events interspersed between the regular
eats (Fig. 6A); 2) development of large-storage release
vents (Fig. 6B); and 3) broad double-humped transients
Fig. 6C). In contrast, only 42% (14 of 41) of control cells
isplayed local Ca2 release events (Fig. 6E), and their ampli-
udes and durations were lower than those noted in the
PVT-cardiomyocytes. Importantly, none of the control
ells developed the more severe whole-cell [Ca2]i transient
irregularities.
In a similar manner to the electrophysiological record-
ings, adrenergic stimulation also worsened the degree of
Ca2 transient abnormalities in the CPVT-hiPSCs-
CMCs. This finding was manifested by the development of
new triggered activity events and/or broad double-humped
transients in 60% (6 of 10) of the CPVT-hiPSCs-CMs after
isoproterenol (1 M) application (Fig. 6F) and in 75% (6 of
) of the cells after forskolin (5M) administration. Incontrast, none of the healthy control cells (n  18 and 13, erespectively) displayed such abnormalities following similar
interventions (Fig. 6G). Because beta-blockers represent the
mainstay treatment for CPVT, we next evaluated their
potential effects on the CPVT-hiPSCs-CMs. Application
of propranolol (5 M) reversed the observed abnormalities
nduced by isoproterenol in 78% (7 of 9) of the cells studied
Fig. 6F).
We next evaluated the effect of Ca2 overload on the
egree of Ca2 transient abnormalities in the hiPSCs-
CMCs. To this end, the cells were perfused with increasing
extracellular Ca2 concentrations ([Ca2]o). As noted in
Figure 6H, this resulted in significant worsening of the
Ca2 transient abnormalities (with development of large,
ide, and double-humped transients) with elevated [Ca2]o
in 75% (6 of 8) of the CPVT-hiPSCs-CMs evaluated.
Store-overload-induced Ca2 release (SOICR). It has
long been appreciated that SR Ca2 release can also occur in
the absence of membrane depolarization through a mecha-
nism referred to as SOICR (6,18). It was also suggested that
some RyR2 mutations may markedly increase the occur-
rence of SOICR (6,18). To evaluate whether SOICR can be
modeled by hiPSCs-CMs, we performed repeated Ca2
imaging in tetrodotoxin-treated hiPSCs-CMs at increasing
extracellular [Ca2]o concentrations (0.1 to 4 mM). As
hown in Figure 7A, SOICR events could be identified in
oth the CPVT and healthy control hiPSC-CMs, with the
umber of Ca2-oscillating cells increasing as function of
[Ca2]o (Fig. 7B). The threshold for generation of SOICR,
owever, was significantly altered by the M4109R RyR2
utation. Consequently, the CPVT-hiPSCs-CMs began to
evelop SOICR at much lower [Ca2]o concentrations when
compared with healthy control cells (Figs. 7A and 7B).
Discussion
In the current study, we demonstrated the unique potential
of hiPSCs for modeling inherited arrhythmogenic syn-
dromes by establishing a patient-specific model of CPVT.
By studying cardiomyocytes differentiated from the CPVT-
hiPSCs, we were able to: 1) recapitulate the disease pheno-
type of the CPVT patient by showing the development of
DADs in the patient-derived hiPSCs-CMs; 2) identify the
role of internal Ca2 stores in the pathogenesis of these
fterdepolarizations; 3) reveal the contribution of the beta-
drenergic signaling pathway to these arrhythmias; 4) show
he ability of the hiPSCs-CMs to develop SOICR with
ncreasing Ca2 concentrations and the significance of the
4109R RyR2 mutation in altering the threshold for such
elease events; and 5) demonstrate the potential of patient-
pecific CPVT-hiPSC-CMs for evaluating candidate drugs
uch as beta-blockers and flecainide.
Since the realization, more than a decade ago, that
utations in the cardiac ryanodine-receptor gene are re-
ponsible for CPVT1 (3,4), much has been learned about
he disease pathogenesis. Experimental findings from het-
rologous expression systems, lipid bilayers, and knock-in
(
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CPVT Modeling With Human-Induced Pluripotent Stem Cells September 11, 2012:990–1000and knockout mice models suggest that the basic mecha-
nism underlying development of arrhythmias in this disor-
der involves a diastolic Ca2 leak from the mutant RyR2
6). This may lead to development of DADs through
ctivation of the membrane Na/Ca2 exchanger, which
can eventually result in triggered activity; the pivotal ar-
rhythmogenic mechanism in CPVT.
One of the challenges in confirming such a mechanism
also clinically was the inability to directly study human
cardiomyocytes from patients with CPVT. The advent of
the hiPSCs technology may solve this cell-sourcing prob-
lem. This unique “disease-in-a-dish” concept is based on
Figure 6 Whole-Cell [Ca2]i Transients in the CPVT and Contro
(A to C) Line-scan images showing changes in intracellular Ca2 in fluo-4 loaded
irregularities manifested as frequent local Ca2 release events (arrows); (B) deve
(D, E) Whole-cell [Ca2]i transients in control hiPSCs-CMs. Although most cells lac
release events (arrows, E). (F) Worsening of Ca2-handling abnormalities in the is
double-humped [Ca2]i transients (middle). Propranolol (5 M) application reverse
hiPSCs-CMs. (H) Effect of extracellular [Ca2]o concentrations on whole-cell [Ca
2
development of broad and double-humped [Ca2]i transients (arrows) in the CPVT-the capacity to derive isogenic hiPSCs from an affectedindividual and to coax their differentiation into the desired
cell lineage (cardiomyocytes), thus portraying the patient-
specific disease phenotype.
We have previously shown that hiPSCs-CMs express the
necessary functional components associated with Ca2 han-
ling (15). This was demonstrated by development of
pontaneous whole-cell [Ca2]i transients in the hiPSCs-
CMs, which were dependent on both sarcolemmal Ca2
entry via L-type Ca2 channels and intracellular store Ca2
release (15).
Here, using hiPSCs-CMs derived from a CPVT patient,
we provide proof-of-concept evidence that the mechanism
SCs-CMCs
iPSCs-CMs. (A) Note the development of significant whole-cell [Ca2]i transient
nt of large store-release Ca2 waves; and (C) broad double-humped transients.
ignificant abnormalities (D), some cells displayed small-amplitude local Ca2
renol-treated (1 M) CPVT-hiPSCs-CMs, manifested by the development of
e abnormalities (right). (G) Isoproterenol did not cause irregularities in control
sients recorded from CPVT (left) and control (right) hiPSCs-CMCs. Note the
-CMs with higher [Ca2]o concentrations. Abbreviations as in Figure 1.l hiP
CPVT-h
lopme
ked s
oprote
d thes
]i tran
hiPSCsthought to underlie arrhythmogenicity in CPVT is also
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September 11, 2012:990–1000 CPVT Modeling With Human-Induced Pluripotent Stem Cellsvalid in the patient-specific cardiomyocytes. This was
shown by the development of DADs in most CPVT-
hiPSCs-CMs that became even more prominent after
activation of the beta-adrenergic signaling pathway and
could eventually give rise to triggered activity.
We next evaluated the role of intracellular Ca2 stores in
the formation of these DADs. By depleting internal Ca2
stores with thapsigargin, we were able to suppress afterde-
polarizations in the CPVT-hiPSCs-CMs, thus confirming
the crucial role of these stores in DADs’ pathogenesis.
Moreover, in a similar manner to the electrophysiological
recordings, laser-confocal Ca2 imaging demonstrated signif-
cant Ca2-handling irregularities in the CPVT-hiPSCs-
CMs. These abnormalities, ranging from an increase in the
incidence and magnitude of local Ca2 release events to more
severe global whole-cell Ca2 irregularities and arrhythmogen-
sis, worsened with beta-adrenergic stimulation and Ca2
Figure 7 SOICR in the CPVT hiPSCs-CMs
(A) Development of store-overload–induced calcium release (SOICR) events in CPV
centrations. Note the development of SOICR events at much lower [Ca2]o concen
CPVT (red) hiPSCs-CMCs displaying Ca2 oscillations at increasing [Ca2]o conce
0.05 when the frequency of Ca2-oscillating cells is compared between the CPVToverload.It is believed that the diastolic Ca2 wave that underlies
the generation of DADs occurs when the SR Ca2 content
exceeds a threshold level. The mechanism for such a
depolarization-independent SR Ca2 release was termed
OICR (6,18), and this process was implicated in the
rrhythmogenesis associated with intracellular Ca2 over-
load, such as during digitalis intoxication. It was also
suggested, in both heterologous expression systems (18,21)
and in cardiomyocytes derived from a mouse model of
CPVT (22), that several RyR2 mutations may markedly
reduce the SR Ca2 threshold required for SOICR. In the
urrent study, we demonstrated the ability of the hiPSCs-
Ms to recapitulate the SOICR phenomenon with the
umber of Ca2-oscillating cells increasing with elevated
a2 concentrations. We also found that the M4109R RyR2
utation decreases the threshold for such events, with SOICR
ccurring in the CPVT-hiPSCs-CMs at much lower Ca2
) and control (right) tetrodotoxin-treated hiPSCs-CMs at different [Ca2]o con-
s in the CPVT cardiomyocytes. (B) Percentage of healthy control (blue) and
ns. Note the reduced threshold for generating SOICR in the CPVT cells. *p 
ntrol cells at each concentration. Abbreviations as in Figure 1.T (left
tration
ntratio
and coconcentrations then in healthy control cells.
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CPVT Modeling With Human-Induced Pluripotent Stem Cells September 11, 2012:990–1000Finally, feasibility studies were performed to demonstrate
the potential of the CPVT-hiPSCs-CMs model for drug
screening. These studies revealed that beta-blockers, which
have been the mainstay treatment for CPVT, may also be
beneficial in the patient-specific hiPSCs-CMs by reversing
the Ca2-handling irregularities observed after adrenergic
timulation. In addition to beta-blockers, potential new
ntiarrhythmic strategies for CPVT include agents targeting
he abnormal diastolic Ca2 leak (e.g., RyR2 stabilizers)
(23) or those targeting the ionic mechanisms responsible for
the generation of triggered activity (6). Flecainide was
recently shown to possess antiarrhythmic properties in
CPVT (20) through either a stabilizing effect on RyR2
(decreasing its opening probability) (20,24) or by increasing
the threshold for triggered activity (through its Na-
channel blocking activity) (25). Although the current study
was not designed to shed additional light on the specific
antiarrhythmic mechanism of flecainide, it did reveal its
ability to eliminate afterdepolarizations and triggered activ-
ity in the patient-derived hiPSCs-CMs. In addition, be-
cause this work involved a single CPVT patient, future
studies will have to expand the results of this study to larger
cohorts of patients.
Taken together, our data demonstrate the unique poten-
tial of hiPSCs-CMs for modeling CPVT. Using this
approach, the disease phenotype presented by the patient at
bedside could be readily recognized in the patient-derived
cells in vitro as an anomalous electrophysiological signature.
Importantly, this study also provided insights into arrhyth-
mia mechanisms in this syndrome and highlighted the
potential of the hiPSCs strategy for screening the effects of
potential disease aggravators (adrenergic stimulation) and custom-
ized treatment options (beta-blockers and flecainide).
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